Latest Market News

Alliance Nickel has confirmed the technical strength of its NiWest project while navigating market headwinds and Stellantis’ offtake renegotiation, as it pursues a Nasdaq listing via SPAC to tap US capital markets.

Light & Wonder, Inc. transitions from an ASX Foreign Exempt Listing to a full ASX Listing, marking a significant regulatory shift without raising new capital. The company continues trading its shares as CHESS Depositary Interests on a 1, 1 basis.

Income Asset Management has appointed Danielle Press as Chair and elevated CEO Jon Lechte to Managing Director, marking a significant leadership transition following the retirement of long-serving Executive Chair John Nantes.

Panther Metals Ltd has initiated a pro rata non-renounceable entitlement offer to raise approximately $816,745, aiming to fund its key exploration projects in gold and base metals. The offer opens on 12 November 2025 and closes on 21 November 2025, inviting eligible shareholders in Australia, New Zealand, and the UK to participate.

Tartana Minerals has inked a non-binding Letter of Intent with Alt Resources for up to $5 million in non-dilutive financing, structured to align repayments with copper production and prices. This deal aims to optimize existing operations and fund expansion through the Mungana processing plant.

Australian Vintage reports a modest sales dip in FY25 but charts a clear path to cash flow neutrality and growth through innovation and strategic acquisitions.

Patronus Resources (ASX – PTN) reveals a robust financial position with $78 million in cash and investments alongside a 2.3 million ounce gold equivalent resource base, underpinning a multi-commodity growth strategy across Western Australia and the Northern Territory.

Sagalio Energy Limited’s shares have been suspended from ASX trading due to compliance concerns, leaving investors in the dark about the company’s next steps.

The FDA's removal of the black box warning on hormone replacement therapies marks a pivotal shift for Mayne Pharma, potentially unlocking new market opportunities and reshaping women’s health treatment.

WCM Global Growth Limited reported a robust FY2025 with net profit soaring to $69.5 million and a 31% portfolio return, prompting increased dividends and a successful $76.7 million capital raise.

Actinogen Medical’s XanaMIA Phase 2b/3 trial for Alzheimer’s disease has received a positive safety recommendation from its independent Data Monitoring Committee, allowing the study to proceed unchanged. Investors now await the critical efficacy analysis scheduled for January 2026.

CVC Limited marked a milestone year with strategic land acquisitions and planning successes, boosting its land portfolio value despite modest net profits. The company’s focus on industrial, residential, and data centre developments positions it for future growth.